We hypothesized that if an efficient immune response against mutated nucleophosmin can be induced in vivo, the individuals expressing HLA alleles suitable for presenting NPM-derived peptides should be less prone to developing AML due to NPM1 mutation. The gene discussed is NPM1; the disease is acute myeloid leukemia.